Con esta herramienta te facilitamos un acceso a todas las ofertas y demandas de tecnología europeas y a búsquedas de socios para participar en propuestas europeas de I+D publicadas en la red Enterprise Europe Network, pudiendo filtrar los resultados para facilitar las búsquedas más acordes con tus necesidades.

¿Quieres recibir estos listados de oportunidades de colaboración en tu correo de forma periódica y personalizada? Date de alta en nuestro Boletín

Para optimizar los resultados de la búsqueda, se recomienda utilizar términos en inglés.

H2020: Búsqueda de experiencia en metabolómica clínica, expresión de genes o proteómica, bases de datos de pacientes y estudios clínicos

Resumen

Tipo:
Búsqueda de socios
Referencia:
RDBG20170111001
Publicado:
26/01/2017
Caducidad:
26/01/2018
Resumen:
Una empresa búlgara de I+D que participa como coordinador de un proyecto busca socios con el fin de formar un consorcio y presentar una propuesta a la convocatoria JTI-IMI2-2016-10. El objetivo es analizar y probar nuevos biomarcadores para el cáncer de próstata. La empresa está especializada en modelización matemática de datos ómicos mediante el uso de su propia plataforma computacional para analizar grandes bases de datos. Se buscan universidades, centros de I+D, pymes, hospitales y laboratorios con experiencia en metabolómica clínica, expresión de genes o proteómica, bases de datos de pacientes y estudios clínicos. La fecha límite de la convocatoria es el 28 de marzo de 2017 y el plazo para presentar expresiones de interés finaliza el 28 de febrero.

Details

Tittle:
H2020: expertise in clinical metabolomics, gene expression or proteomics, patient data bases and clinical studies sought
Summary:
Bulgarian R-Y-D company looks for partners to build a project consortium as coordinator under JTI-IMI2-2016-10 for analysing and testing novel biomarkers for prostate cancer. They are specialised in mathematical modeling of various types of ´omics´ data using own computational platform for big data analyses. Partners sought are universities, R-Y-D institutes, SMEs, hospitals and labs with expertise in clinical metabolomics, gene expression or proteomics, patient data bases, clinical studies.
Description:
The Bulgarian R-Y-D company has designed a versatile big data computational platform for modelling of biomolecular interactions and pathways. The applications of the computational platform include drug discovery and design, repositioning of therapeutic compounds, small-molecule diagnostics, chemical genetics, biomarker identification, etc.

The company is building up a consortium as coordinator for submitting a project proposal under the H2020-JTI-IMI2-2016-10-two-stage, Topic: How Big Data could support better diagnosis and treatment outcomes for Prostate Cancer.

The main objective of the proposal is to deploy the capacity of the big data computational platform for discovering disease signatures of the prostate cancer. The platform has a wide range of useful functionalities such as:
- using combination of biomarkers of various types (genomic, gene-expression, proteomic and metabolomic) as flexible solutions for non-invasive diagnostic tools;
- modelling patient´s metabolomics data for the creation of highly specific disease signature profiles;
- ability to find predictive multi-factorial biomarker signatures without the need of an exhaustive search of all possible combinations of individual biomarkers;
- screening both asymptomatic and symptomatic patients, and unambiguously differentiate between positive and negative symptomatic.

The company has already developed a portfolio of predictive cancer signatures for ovarian, prostate, bladder and breast cancer from publicly available gene expression, metabolomics and proteomics data. Those preliminary data can be further used in the project activities.

The main outcomes of the project activities would be the discovery of novel biomarkers for diagnosis, prognosis and targeted therapy for prostate cancer.

The company is looking for research and business partners that can provide expertise in clinical metabolomics, gene expression or proteomics, data from patients with prostate cancer, as well as laboratories able to validate potential novel biomarkers detected in the course of the project.

The project proposal would have the following indicative structure:

WP 1: Project management and administration
WP 2: Disease understanding and outcome definition
WP 3: Data access and sources
WP 4: Data platform
WP 5: Data analytics
WP 6: Clinical validation
WP 7: Dissemination and communication

The WPs will encompass different tasks for discovering patterns relating the prostate cancer grade, stage and molecular markers, and for developing predictive models of patient outcomes, disease progression and therapy selection.

Call title: H2020-JTI-IMI2-2016-10-two-stage:
Topic: How Big Data could support better diagnosis and treatment outcomes for Prostate Cancer

Types of action: IMI2-RIA Research and Innovation action

Call information https://ec.europa.eu/research/participants/portal/desktop/en/opportunities/h2020/topics/imi2-2016-10-02.html

Deadline of the call, 1 stage submission: 28 March 2017
Deadline for submitting EoI: 28 February 2017
Stage of Development:
Proposal under development

Partner sought

Partner Sought:
The company looks for the following project partners: - R-Y-D organisation, university and/or R-Y-D company with expertise in clinical metabolomics, gene expression or proteomics data. The main tasks will be to analyse, develop and validate novel biomarkers for discovering predictive disease signatures for prostate cancer. - Hospitals, patients organisations or companies for clinical research with main role to provide and analyse data on patients with prostate cancer. - Laboratories and/or companies for clinical research to test and validate the biomarkers.
Type of Partnership Considered:
RDR

Client

Type and Size of Client:
Industry SME <= 10
Already Engaged in Trans-National Cooperation:
Si
Languages Spoken:
English

Dissemination

Programme-call

Evaluation Scheme:
Two-stage proposal submission: first stage: 28 March 2017 17:00:00 second stage: 14 September 2017 17:00:00
Coordinator Required:
No
Deadline for Call:
28/03/2017
Project Duration:
0